Updated Recommendations on Nonstatin Therapies for Managing LDL-C: Health System Considerations for ASCVD Risk Management

Evolving Recommendations for Nonstatin Use in Patients with ASCVD

Key Treatment Considerations and Takeaways from the 2022 Expert Consensus Decision Pathway

Systematically Implementing Innovative Care Models in Lipid Management

Overcoming Barriers and Improving Access to Nonstatin Therapies

Final Thoughts on Updated Expert Consensus Decision Pathway Recommendations

Meet the Speakers

Tyler Gluckman, MD, MHA, FACC, FAHA, FASPC


Tyler Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director
Center for Cardiovascular Analytics,
Research, and Data Science
Providence Heart Institute
Portland, OR

Nihar Desai, MD

Nihar Desai, MD, MPH

Associate Professor, Yale School of Medicine
Vice Chief, Cardiovascular Medicine
New Haven, CT

Seth Martin, MD, MHS

Seth Martin, MD, MHS

Associate Professor of Medicine (Cardiology)
Johns Hopkins University School of Medicine
Baltimore, MD

Alan S. Brown, MD, MHA, FACC, MNLA

Alan S. Brown, MD, MHA, FACC, MNLA

Director, Division of Cardiology and the Lipid Clinic, Advocate Lutheran General Hospital Clinical Associate Professor, Loyola University Chicago Stritch School of Medicine Past President, National Lipid Association
Downers Grove, IL

Panelists were compensated for their time. Insights shared reflect individual experiences and perspectives.


In this on-demand broadcast, the experts will:

Examine the role of nonstatin therapies for LDL-C in the management of ASCVD, including opportunities to address gaps in care for improving uptake of optimal medication management

Discuss system-level considerations when implementing new lipid management recommendations to promote population health initiatives aimed at reducing CV risk in ASCVD patients and improving health outcomes


©2022 Amgen Inc. All rights reserved.  
USA-145-84201 12/22